A PYMNTS Company

EU: Pay-for-delay schemes remain top focus for regulators

By  |  February 26, 2013

As both US and EU antitrust regulators discuss the fight against pay-for-delay agreements, seen as anticompetitive for the pharmaceuticals market, the European Commission is reporting an increased number of cases against brand name drug makers concerning the agreements. At the Reuters Euro Zone Summit, Commissioner Joaquin Almunia announced additional cases are headed towards the regulator as more than a dozen drug companies have already been under fire and encompassed under four investigations by the Commission. In outlining the Commissions’ plan of attack to combat the anticompetitive actions, which could lead to consumers paying more for drugs as generics are kept off the shelves, Almunia noted that while those who hold patents to a drug must be protected, once those patents expire, “all citizens should have the right” to access the generics and, therefore, cheaper drugs. The companies involved in the ongoing investigations were not named at the Summit.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    Subscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

     

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.